Are All HA (Hyaluronic Acid) Fillers the Same? Brand Differences Matter More Than You Think
"My doctor used hyaluronidase three times, but my Voluma lumps barely changed. I thought all HA could be dissolved?" At FILLER REVISION, we encounter this frustration regularly. Patients assume all hyaluronic acid fillers respond identically to dissolution — but they do not. Different HA brands differ significantly in cross-linking technology, particle structure, cohesivity, and rheological properties, directly influencing how they respond to treatment.
At FILLER REVISION, years of managing filler complications across every major brand has revealed distinct "complication tendencies" for each product line. Understanding these differences guides correct management strategies when standard dissolution fails.
Key Insight: At FILLER REVISION, we see this pattern regularly — "all HA fillers can be dissolved with hyaluronidase" is theoretically correct, but the response speed and dose requirements vary dramatically between brands. This is a critical consideration that determines whether dissolution alone will work or extraction becomes necessary.
Technical Differences Among Major HA Brands
Cross-Linking Technology Comparison
← Swipe to see more →
| Brand | Cross-Linking Technology | Characteristics | Key Product Lines |
|---|---|---|---|
| Juvéderm | VYCROSS | High/low MW HA blend cross-linking | Voluma, Volift, Volbella |
| Restylane | NASHA (Non-Animal Stabilized Hyaluronic Acid) / OBT (Optimal Balance Technology) | Minimal modification / optimal balance | Lyft, Defyne, Refyne |
| Haiwei | Cross-linked HA | Common in Asian markets | Multiple formulations |
| Princess | S.M.A.R.T. | High-purity HA | Volume, Filler, Rich |
| Megafill | Cross-linked HA | Regional Asian brand | Multiple formulations |
Rheological Properties and Clinical Behavior
Research on gel properties and persistence has demonstrated that cross-linking degree directly determines how each HA brand behaves in tissue and responds to enzymatic degradation (Edsman et al., 2012). Studies on cohesivity have further shown that these rheological differences are clinically meaningful for predicting complication patterns (Sundaram et al., 2015).
← Swipe to see more →
| Property | High Cohesivity Products | Low Cohesivity Products |
|---|---|---|
| Representative brand | Juvéderm Voluma | Restylane |
| Tissue behavior | Tends to maintain bolus shape | Disperses more readily into tissue |
| Sculpting ability | Stronger | Softer |
| Migration (Filler Migration) tendency | Low (but displaces as a unit if it occurs) | Moderate (gradual diffusion) |
| Hyaluronidase response | May require higher dose/more time | Generally responds faster |
Complication Risk Profiles by Brand
Juvéderm Series
VYCROSS technology characteristics: High cohesivity maintains better shape stability in tissue, but this also means:
← Swipe to see more →
| Complication Type | Risk Level | Notes |
|---|---|---|
| Tyndall effect | Moderate | Blue discoloration possible with superficial injection |
| Delayed swelling | Moderate to high | VYCROSS products have higher hydrophilicity |
| Hyaluronidase resistance | Moderate to high | Higher cross-linking may require more enzyme |
| Vascular occlusion | Low to moderate | Comparable to all HA fillers |
| Lump formation | Low to moderate | High cohesivity sometimes creates palpable masses |
Clinical observation: Juvéderm Voluma, due to its high cohesivity, may require higher hyaluronidase doses and longer reaction times when dissolution is needed compared to other brands.
Restylane Series
NASHA/OBT technology characteristics: More traditional cross-linking approach with a broader texture range:
← Swipe to see more →
| Complication Type | Risk Level | Notes |
|---|---|---|
| Tyndall effect | Moderate to high | More noticeable with some products at superficial depth |
| Delayed swelling | Low to moderate | Relatively lower hydrophilicity |
| Hyaluronidase response | Good | Generally responds faster to enzyme dissolution |
| Nodule formation | Low to moderate | Particulate products occasionally produce palpable nodules |
| Migration | Moderate | Lower cohesivity products may diffuse over time |
Asian Market Brands
The Asian market features numerous HA brands with variable quality:
← Swipe to see more →
| Risk Factor | Details |
|---|---|
| Quality control variability | Batch-to-batch consistency may be insufficient |
| Unstable cross-linking | May lead to unpredictable degradation rates |
| Impurity residue | Lower-purity products may trigger more inflammatory reactions |
| Hyaluronidase response | Some brands respond less predictably to enzyme |
Key Insight: Brand selection is not only about results — it is fundamentally about safety. Choosing brands with extensive clinical data ensures more predictable management options if complications arise.
The Myth That "All HA Can Be Dissolved"
Theory Versus Reality
All HA fillers can theoretically be degraded by hyaluronidase. However, clinical reality introduces several variables:
← Swipe to see more →
| Factor | Impact on Dissolution |
|---|---|
| Cross-linking degree | Higher cross-linking requires more enzyme and more time |
| Time since injection | Long-standing HA may be partially encapsulated |
| Volume injected | Large volumes require staged dissolution |
| Injection site | Areas with fewer vessels see slower enzyme diffusion |
| Brand differences | Different cross-linking technologies respond differently to enzyme |
Common Reasons for Dissolution Failure
- Insufficient dosing: Underestimating filler volume or cross-linking density
- Imprecise injection: Enzyme not making direct contact with the filler
- Capsule barrier: Long-standing filler encased in fibrous capsule blocks enzyme penetration
- Non-HA components: Some products may contain additives not degraded by hyaluronidase
- Misidentification: The injected material is not actually HA (told it was HA but was not)
For more on how encapsulation affects dissolution, see Why Dissolving Enzymes Fail When Capsules Form.
The Role of Ultrasound (Ultrasonography) in Brand Identification and Management
Ultrasound Appearance of Different Brands
While ultrasound cannot definitively identify specific brands, it provides important clues:
← Swipe to see more →
| Ultrasound Feature | Possible Interpretation |
|---|---|
| Homogeneous hypoechoic mass | High-cohesivity product (e.g., Voluma) |
| Scattered hypoechoic dots | Particulate product (e.g., classic Restylane) |
| Hypoechoic area with capsule | Long-standing filler |
| Hypoechoic area without clear borders | Low-cohesivity or partially degraded product |
Ultrasound-Guided Management Strategies
← Swipe to see more →
| Scenario | Management Approach |
|---|---|
| HA amenable to dissolution | Ultrasound-guided precise hyaluronidase injection |
| Partially encapsulated HA | Attempt dissolution first; extraction if insufficient |
| Fully encapsulated HA | Ultrasound-guided minimally invasive extraction |
| Uncertain if HA | Ultrasound assessment before deciding strategy |
When Brand-Specific Properties Defeat Standard Dissolution: The FILLER REVISION Approach
At FILLER REVISION, we have developed brand-aware treatment protocols because a one-size-fits-all approach to HA complications consistently underperforms. High-cohesivity products like Juvéderm Voluma may require significantly higher hyaluronidase doses and longer exposure times than standard protocols account for. Encapsulated HA — regardless of brand — resists enzymatic penetration entirely. Our approach begins with ultrasound assessment that identifies not just filler location but its characteristics, guiding our decision between optimized dissolution protocols, ultrasound-guided extraction, or a combined approach. This brand-informed strategy is why patients who failed standard dissolution elsewhere often achieve resolution at FILLER REVISION.
Recommendations for Filler Selection
Principles for Reducing Complication Risk
← Swipe to see more →
| Principle | Explanation |
|---|---|
| Choose brands with clinical data | Prioritize global brands with robust safety evidence |
| Understand filler properties | Different sites require different rheological characteristics |
| Inject conservatively | Less is more; additional volume can be added later |
| Document injection details | Brand, lot number, volume, site — critical for future management |
| Choose a practitioner who manages complications | Can prevent, recognize, and treat |
Already Experiencing Problems? Let Us Help
If you've already tried treatment for HA filler complications without success, FILLER REVISION specializes in exactly these cases. Our brand-aware protocols address the specific dissolution challenges each product presents.
Further reading:
- Is HA Really Completely Absorbed?
- Why Dissolving Enzymes Fail When Capsules Form
- Why Fillers Migrate
Frequently Asked Questions
My doctor used hyaluronidase several times but my filler lumps barely changed. Why didn't the dissolving enzyme work?
Although all HA fillers can theoretically be degraded by hyaluronidase, the response speed and dose requirements vary dramatically between brands. Common reasons dissolution fails include insufficient dosing, the enzyme not making direct contact with the filler, a fibrous capsule around long-standing filler blocking enzyme penetration, non-HA additives that hyaluronidase does not degrade, or the injected material not actually being HA. Higher cross-linking requires more enzyme and more time, so a high-cohesivity product may simply need a different, brand-aware protocol rather than more of the same.
Aren't all hyaluronic acid (HA) fillers the same? Why would the brand affect how easily mine dissolves?
Different HA brands differ significantly in cross-linking technology, particle structure, cohesivity, and rheological properties, which directly influence how they respond to treatment. High-cohesivity products such as Juvéderm Voluma tend to maintain a bolus shape in tissue and may require higher hyaluronidase doses and longer reaction times, while lower-cohesivity products generally respond faster. Brands also use distinct cross-linking technologies (VYCROSS, NASHA, OBT) that affect their complication patterns. So the brand is not a cosmetic detail — it shapes whether dissolution alone will work or extraction becomes necessary.
My filler has been in for a long time. Does that make it harder to dissolve, and what can be done?
Long-standing filler may become partially or fully encased in a fibrous capsule, and an encapsulated HA filler resists enzymatic dissolution regardless of brand because the capsule blocks hyaluronidase from reaching the filler core. For partially encapsulated HA, the approach is to attempt dissolution first and proceed to extraction if that is insufficient; for fully encapsulated HA, ultrasound-guided minimally invasive extraction is used. Ultrasound assessment is done first to identify the capsule and the filler's characteristics before deciding the strategy.
I don't know which brand of filler I was injected with. Can it still be assessed and treated?
Ultrasound cannot definitively identify the specific brand, but it provides important clues about the filler's characteristics — for example, a homogeneous hypoechoic mass suggests a high-cohesivity product, scattered hypoechoic dots suggest a particulate product, and a hypoechoic area with a capsule suggests long-standing filler. Assessment begins with ultrasound that identifies not just the filler's location but its characteristics, which then guides the choice between dissolution, ultrasound-guided extraction, or a combined approach. If it is uncertain whether the material is even HA, ultrasound assessment is done before deciding the strategy.
What can I do before getting filler to make any future complications easier to manage?
Documenting the exact brand, lot number, volume, and injection site at the time of treatment is critical for effective complication management later. It also helps to choose global brands with robust safety evidence, since brands with extensive clinical data offer more predictable management options if complications arise. Injecting conservatively (less is more, with volume added later if needed) and choosing a practitioner who can prevent, recognize, and treat complications further reduce risk.
About the Author
Dr. Ta-Ju Liu
- Current Position: Director, Liusmed Clinic
- Specialties: Minimally invasive surgery, filler complication repair, ultrasound-guided extraction
- Experience: 15+ years of clinical minimally invasive surgery; over 10,000 successful cases
- Philosophy: "Brand selection is the first line of defense in filler safety. Understanding different brands' characteristics and risks ensures more effective management when it is needed."
